Evidence map›Paper›PMID 39516725›Full record

ArticleBMC infectious diseases2024

Malaria treatment for prevention: a modelling study of the impact of routine case management on malaria prevalence and burden.

Flavia Camponovo, Aurélie Jeandron, Laura A Skrip, Monica Golumbeanu, Clara Champagne, Tasmin L Symons, Mark Connell, Peter W Gething, Theodoor Visser, Arnaud Le Menach and 2 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Flavia CamponovoSwiss Tropical and Public Health Institute, Basel, Switzerland. flavia.camponovo@unibas.ch.
Aurélie JeandronSwiss Tropical and Public Health Institute, Basel, Switzerland.
Laura A SkripUniversity of Liberia School of Public Health, Monrovia, Liberia.
Monica GolumbeanuSwiss Tropical and Public Health Institute, Basel, Switzerland.
Clara ChampagneSwiss Tropical and Public Health Institute, Basel, Switzerland.
Tasmin L SymonsTelethon Kids Institute, Perth Children's Hospital, Perth, Australia.
Mark ConnellTelethon Kids Institute, Perth Children's Hospital, Perth, Australia.
Peter W GethingTelethon Kids Institute, Perth Children's Hospital, Perth, Australia.
Theodoor VisserClinton Health Access Initiative, Boston, USA.
Arnaud Le MenachClinton Health Access Initiative, Boston, USA.
Justin M CohenClinton Health Access Initiative, Boston, USA.
Emilie PothinSwiss Tropical and Public Health Institute, Basel, Switzerland.

Funding

Bill and Melinda Gates Foundation INV-009390/OPP1197730Bill and Melinda Gates Foundation OPP1109772/INV-008108
6 · The paper itself

Abstract

backgroundTesting and treating symptomatic malaria cases is crucial for case management, but it may also prevent future illness by reducing mean infection duration. Measuring the impact of effective treatment on burden and transmission via field studies or routine surveillance systems is difficult and potentially unethical. This project uses mathematical modeling to explore how increasing treatment of symptomatic cases impacts malaria prevalence and incidence.

methodsLeveraging the OpenMalaria stochastic agent-based transmission model, we first simulated an array of transmission intensities with baseline effective treatment coverages of 28%, 44%, and 54% incorporated to reflect the 2023 coverage distribution across Africa, as estimated by the Malaria Atlas Project. We assessed the impact of increasing coverage to as high as 60%, the highest 2023 estimate on the continent. Subsequently, we performed simulations resembling the specific subnational endemicities of Kenya, Mozambique, and Benin, using the Malaria Atlas Project estimates of intervention coverages to reproduce historical subnational prevalence. We estimated the impact of increasing effective treatment coverage in these example settings in terms of prevalence reduction and clinical cases averted in children under 5 years old and the total population.

resultsThe most significant prevalence reduction - up to 50% - was observed in young children from lower transmission settings (prevalence below 0.2), alongside a 35% reduction in incidence, when increasing effective treatment from 28% to 60%. A nonlinear relationship between baseline transmission intensity and the impact of treatment was observed. Increasing effective treatment coverage to 60% reduced the risk in high-risk areas (prevalence in children under 5 years old > 0.3), affecting 39% of young children in Benin and 20% in Mozambique previously living in those areas. In Kenya where most of the population lives in areas with prevalence below 0.15, and case management is fairly high (53.9%), 0.39% of children were estimated to transition to lower-risk areas.

conclusionsImproving case management directly reduces the burden of illness, but these results suggest it also reduces transmission, especially for young children. With vector control interventions, enhancing case management can be an important tool for reducing transmission intensity over time.

Indexed as

Case ManagementMalariaAfricaAntimalarialsChild, PreschoolCost of IllnessHumansIncidenceInfantKenyaModels, TheoreticalMozambiquePrevalenceAntimalarialsMalariaModellingP. FalciparumTransmissionTreatment

Identifiers

PMID39516725
PMCPMC11549775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.